Reply to Malignant pericardial effusion: Sclerotherapy or local chemotherapy

British Journal of Cancer

Volumn 101, Issue 4, 2009, Pages 736-737

  Kunitoh, H ^a   Tamura, T ^b   Saijo, N ^c  

^a MITSUI MEMORIAL HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; PLATINUM; TETRACYCLINE; THIOTEPA; VINBLASTINE;

CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LETTER; LUNG CANCER; MALIGNANT PERICARDIAL EFFUSION; PERICARDIAL EFFUSION; PRIORITY JOURNAL; SCLEROTHERAPY; TREATMENT OUTCOME;

EID: 68749099650     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605223     Document Type: Letter

References (4)

1. Gornik HL, Gerhand-Herman M, Beckman JA (2005) Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion. J Clin Oncol 23: 5211-5216
2. Kunitoh H, Tamura T, Shibata T, Imai M, Nishiwaki Y, Nishio M, Yokoyama A, Watanabe K, Noda K, Saijo N (2009) A randomized trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811). Br J Cancer 100: 464-469
3. Lestuzzi C, Lafaras C, Bearz A, Gralec R, Viel E, Buonadonna A, Bischiniotis T (2009) Malignant pericardial effusion: sclerotherapy or local chemotherapy? Br J Cancer [epub ahead of print]
4. Press OW, Livingston R (1987) Management of malignant effusion and tamponade. JAMA 257: 1088-1092